Masimo Co. (NASDAQ:MASI) Given Average Recommendation of “Moderate Buy” by Brokerages

Masimo Co. (NASDAQ:MASI) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $179.67.

MASI has been the topic of several research analyst reports. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler boosted their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd.

Masimo Stock Up 1.6 %

Shares of NASDAQ:MASI opened at $171.23 on Wednesday. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm’s 50-day simple moving average is $165.55 and its 200-day simple moving average is $137.46. The company has a market cap of $9.17 billion, a price-to-earnings ratio of 118.09 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. As a group, equities research analysts predict that Masimo will post 4.03 earnings per share for the current year.

Hedge Funds Weigh In On Masimo

Several hedge funds have recently bought and sold shares of MASI. NBC Securities Inc. boosted its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. MML Investors Services LLC boosted its stake in shares of Masimo by 4.9% during the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after purchasing an additional 96 shares during the last quarter. Oak Thistle LLC grew its holdings in shares of Masimo by 5.2% during the second quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC raised its position in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Masimo by 12.7% in the third quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.